Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

ENV-101

Phase 2Small molecule

EEndeavor Biomedicines, Inc.

ENV-101 is one of 32 small molecule programs targeting Fibrosis. It is currently in Phase 2.

1

Indications

2

Total Trials

1

Active Trials

31

Competitors

Pipeline

Status by Indication[3][1]

Indication

FibrosisActive, not recruiting

FibrosisPhase 2

Active, not recruiting

Competition

Competitive Landscape

35 competitors in Fibrosis

#DrugCompanyPhaseTrials

Cellcept

Vemlidy

Lexiscan

Neoral

Esbriet

LLegacy Health System

Glucophage

Rayos

RRoxane Laboratories

Rapamune

PPrism Pharmaceuticals

Actemra

Viagra

VViatris Specialty LLC

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Fibrosis

NCT06422884

Clinical

Trials by Indication[1]

Patients With Advanced Solid Tumors1 trial

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

Completed·EEndeavor Biomedicines, Inc.·Phase 2·NCT05199584·20 enrolled

Fibrosis1 trial

A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)

Active, not recruiting·EEndeavor Biomedicines, Inc.·Phase 2·NCT06422884·213 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for ENV-101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ENV-101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ENV-101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Endeavor Biomedicines, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: EEndeavor Biomedicines, Inc.

Related News